Close Menu

NEW YORK – After changing its name this summer, Helio Health (formerly Laboratory for Advanced Medicine) now aims to validate its circulating tumor DNA (ctDNA)-based hepatocellular carcinoma (HCC) screening assay by comparing it to standard ultrasound screening with the US launch of a multi-center collaboration.

The Irvine, California-based firm also hopes to raise more than $100 million in a funding round by the end of the year to launch its liver test in the US and China in 2021, as well as to further develop assays for colon, breast, and lung cancers.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.